Next Article in Journal
Vitamin D and Male Reproduction: Updated Evidence Based on Literature Review
Next Article in Special Issue
Glycation-Driven Inflammation: COVID-19 Severity in Pregnant Women and Perinatal Outcomes
Previous Article in Journal
Pregnancy and COVID-19: The Possible Contribution of Vitamin D
Previous Article in Special Issue
Second-Trimester Constituents of the Metabolic Syndrome and Pregnancy Outcome: An Observational Cohort Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 14
Issue 16
10.3390/nu14163276
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hypertensive Disorders of Pregnancy and Fetal Growth Restriction: Clinical Characteristics and Placental Lesions and Possible Preventive Nutritional Targets

by
Daniela Denis Di Martino
1,†,
Laura Avagliano
2,†,
Enrico Ferrazzi
1,3,*,
Federica Fusè
4,
Vittoria Sterpi
1,
Marco Parasiliti
1,
Tamara Stampalija
5,6,
Sara Zullino
7,
Antonio Farina
8,
Gaetano Pietro Bulfamante
2,9,
Matteo Di Maso
10 and
Francesco D’Ambrosi
1
1
Department of Woman, Child and Neonate, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
2
Department of Health Sciences, San Paolo Hospital, ASST Santi Paolo e Carlo, 20142 Milano, Italy
3
Department of Clinical and Community Health Sciences, University of Milan, 20122 Milan, Italy
4
Department of Woman, Mother and Neonate, Buzzi Children’s Hospital, 20154 Milan, Italy
5
Unit of Fetal Medicine and Prenatal Diagnosis, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, 34137 Trieste, Italy
6
Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy
7
Department of Obstetrics and Gynaecology, Pisan University Hospital, 56124 Pisa, Italy
8
Division of Obstetrics and Prenatal Medicine, Department of Medicine and Surgery (DIMEC), Sant’Orsola-Malpighi Hospital, University of Bologna, 40126 Bologna, Italy
9
Unit of Human Pathology, San Paolo Hospital, ASST Santi Paolo e Carlo, 20142 Milan, Italy
10
Department of Clinical Sciences and Community Health, Branch of Medical Statistics, Biometry and Epidemiology “G.A. Maccacaro”, University of Milan, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Nutrients 2022, 14(16), 3276; https://doi.org/10.3390/nu14163276
Submission received: 27 June 2022 / Revised: 4 August 2022 / Accepted: 8 August 2022 / Published: 10 August 2022
(This article belongs to the Special Issue The Interplay between Maternal Nutrition and Oxidative Stress)
Versions Notes

Abstract

:
Background: The purpose of this study was to describe the placental lesions in pregnancies complicated by hypertensive disorders (HDP) and/or fetal growth restriction (FGR) and in uneventful control pregnancies. Methods: This is a case control study that included singleton pregnancies with HDP and normally grown fetus (HDP-AGA fetus), with HDP and FGR, early FGR, late FGR, and uneventful pregnancies. Feto-placental Doppler velocimetry and sFlt-1/PlGF ratio were performed. Placental histology was evaluated blinded according to the Amsterdam Consensus criteria. Results: Placental lesions with maternal vascular malperfusion (MVM) were significantly more frequent in HDP-FGR and early FGR (92% and 83%). MVM were significantly associated with abnormal feto-placental Doppler parameters, especially in early FGR. Delayed villous maturation (DVM) was associated with late FGR (83%). HDP-AGA fetus cases presented a heterogeneous pattern of placental lesions, including 60% of cases with MVM, but were not associated with abnormal Doppler feto-placental velocimetry. Conclusions: We found a prevalence of placental maternal vascular malperfusion in HDP-FGR and early FGR groups. These lesions were also associated with abnormal, anti-, and angiogenic markers. Conversely HDP-AGA fetus and late FGR presented more heterogeneous placental lesions not severe enough to cause feto-placental Doppler anomalies. These conditions are likely associated with different etiologies, such as maternal pre-pregnancy risk factors for metabolic syndrome. These findings suggest a possible preventive nutritional approach in addition to low-dose aspirin in pregnant women with predisposing factors for HDP-AGA fetuses and late FGR.

1. Introduction

Hypertensive disorders of pregnancy (HDP) and fetal growth restriction (FGR) are among the most relevant obstetrical syndromes associated with maternal and/or fetal morbidity and mortality [1]. Among the different hypertensive disorders, even preeclampsia (PE), possibly the most severe form of HDP, is widely acknowledged as a syndrome [2] rather than as a single disease occurring with different complications at different gestational ages. Indeed, various clinical-pathogenetic phenotypes of HDP have been proposed: on one side, early shallow trophoblastic invasion with poor placental and fetal growth and, on the other side, maternal “cardiovascular and metabolic risk factors for endothelial dysfunction” [3], both leading to oxidative stress [4,5].
In the placenta, the exchange of nutrients and oxygen between mother and fetus occurs at the interface of the placental villi with their vasculosyncytial membranes and the intervillous space in contact with the maternal blood [6]. In physiological pregnancy, during implantation, there is an invasion of extravilli trophoblasts in the maternal decidua and spiral arteries with consequent remodeling and formation of a low-resistance circulation in the intervillous space [7]. When this invasion process is compromised, various types of placental lesions can occur, which impair maternal-fetal exchanges and can manifest in pregnancy complications [8]. Both PE and FGR present histological alterations of the placenta which, although in part are different from each other, are acuminated by ischemic damage [4,5,9,10]. In placental ischemia, there is an alteration of the balance between reactive oxygen species (ROS), including superoxide anion (O2-) and hydrogen peroxide (H2O2) and antioxidants. This event is the cause of oxidative stress, which causes damage to proteins, lipids, and DNA [3,4,5,11,12]. In this way, large amounts of ROS are formed in cell membranes, endoplasmic reticulum, and mitochondria [11]. The antioxidant factors produced by the placenta and the nitric oxide (NO) vasodilator are unable to compensate for this alteration, which can lead to some serious complications [11]. The relative role of maternal hemodynamics [13,14], of patterns of fetal growth [15,16], and placental histology [17,18,19] in relation to HDP, FGR, or both [20,21,22] still need to be elucidated, as it is currently difficult to develop therapeutic or preventive strategies [5].
Moreover, recent research findings pointed out suboptimal maternal diet [23,24,25] and maternal stress as potentially important contributors [26]. We hypothesize that the analysis of the placental histology might contribute to differentiate the phenotypes of HDP and of FGR as well as their possible overlapping in the real-life clinical scenario. The purpose of this study is to describe and analyze placental histological characteristics and their possible association with different phenotypes of hypertensive disorders of pregnancy, fetal growth restriction, and in uneventful pregnancies. This association could help to design future preventive and therapeutic strategies.

2. Materials and Methods

2.1. Study Design and Participants

This is a case-control study performed at the high-risk clinic of the Maternal-Fetal Medicine Unit, tertiary referral center, University of Milan. The Ethical Committee approved the study (Ethical Committee NN Milano 10818).
All admitted singleton pregnancies affected by HDP and/or FGR who signed the research consent were included in the study. Controls were enrolled from the low-risk [27] outpatient clinic when a case was recruited and followed until delivery. Participants were eligible for the analysis only if a complete follow-up of pregnancy outcome was available.
HDP was diagnosed and classified according to the Canadian Guidelines from the Society of Obstetrics and Gynaecology of Canada (SOGC) [16], with the exclusion of chronic hypertension. Gestational age was determined by the fetal crown–rump length (CRL) [28], and fetal growth was assessed on the recorded measurements obtained by routine ultrasound measurements.
FGR was defined when the abdominal circumference (AC) was ≤10th percentile for local standards or crossed more than 2 quartiles on growth charts from the mid-trimester scan. Early and late FGR were defined according to the Delphi criteria [29]. Fetuses with an AC >10th percentile and normal uterine and umbilical Doppler velocimetry were diagnosed as having an appropriate fetal growth (AGA fetus).
Exclusion criteria included: maternal age <18 years, pregnant women with fetuses affected by chromosomal abnormalities, multiple pregnancies, congenital infections or malformations, and refusal to participate.
We excluded pregnant women who had possible comorbidities that could influence the development of the placenta and with direct and indirect risk factors, such as chronic hypertension, pre-existing diabetes, or congenital and/or acquired thrombophilia, and pregnancies conceived by in vitro fertilization.
Patients who agreed to participate in the study and who did not meet exclusion criteria were divided into the following groups based on clinical and ultrasound characteristics: (1) pregnancies complicated by HDP and associated with AGA fetus (HDP-AGA fetus); (2) pregnancies complicated by HDP and associated with FGR (HDP-FGR); (3) normotensive patients with early (gestational age ≤ 32 weeks) FGR (early FGR); (4) normotensive patients with late (gestational age > 32 weeks) FGR (late FGR); and (5) uneventful control pregnancies.
Maternal, obstetric, and neonatal characteristics as well as biophysical and biochemical markers were collected. In particular, maternal characteristics included gestational age at recruitment (weeks), age (years), pre-pregnancy BMI (kg/m2), smoking status during pregnancy (never or current), family history of hypertension, and parity. Obstetric characteristics included gestational age at delivery (weeks), obstetric history (previous HDP or FGR), and delivery mode (spontaneous labor, induction, and caesarean section). Neonatal characteristics included weight percentile, neonatal intensive care unit (NICU) admission, perinatal morbidity (at least one of the following: jaundice, anemia, hypoglycemia, hypocalcemia, polycythemia, respiratory distress syndrome, patent ductus arteriosus, gastro-esophageal reflux, acute kidney insufficiency, neonatal hemolysis, pneumothorax, necrotizing enterocolitis, infections, and hypoxic-ischemic encephalopathy), and neonatal death. Biophysical markers measurements included fetal biometry and Doppler interrogation of the uterine (UtA) and umbilical arteries (UA) and middle cerebral artery (MCA).

2.2. Assessment of Biochemical Marker

At recruitment, the concentration of placental vascular growth factors (PlGF) and soluble blocking factors (sFlt-1) was measured. Blood samples were collected in a 3.5 mL test tube containing acrylic gel. Blood samples were then centrifuged to obtain the serum and stored at −80 degrees. The samples were defrosted within 6 months of collection (to avoid serum deterioration), and sFlt-1 and PlGF concentrations were measured using the automatic Elecsys immunoassays (ROCHE), technology based on an automated immunofluorescence concentration and an ELISA immunoassay. The clinical staff was blinded to biomarkers results.

2.3. Placental Examination

The macroscopic analysis of the placenta included an extensive evaluation of the maternal and fetal plates, the umbilical cord, and membranes. Placental was evaluated in a blinded fashion using the Amsterdam Placental Workshop Group Consensus criteria [10]. According to standard international methods [10], at least five blocks of tissue samples were obtained for each placenta: one roll of the free membrane (chorion and amnion with attached decidua capsularis), one block containing 3 cross-sections of the umbilical cord (one from the fetal end, one near the placental insertion of the cord, and one midway between the fetal and placental ends of the cord), and three blocks containing full-thickness sections of grossly normal placental parenchyma (one at the center close to the umbilical cord insertion, one at the margin, and one midway between these two). If present, all macroscopic lesions have been described, and a block of grossly identified lesion was sampled as well, with the adjacent normal parenchyma.
Formalin-fixed, paraffin-embedded placental tissue samples were processed for conventional histopathological examination, and standard 4 mm thick tissue sections, stained with hematoxylin and eosin, were examined by light microscopy.
Placental histology was analyzed by a senior dedicated pathologist (G.B.). The pathologist was blinded to clinical characteristics except for the gestational age at delivery since some of the pathological findings are closely dependent on gestational age (i.e., maturation of placental parenchyma). Other clinical parameters were not provided to the pathologist.

2.4. Statistical Analysis

Categorical variables were expressed as absolute frequencies (n) and proportions (%), whereas continuous variables were expressed as means ± standard deviations (SD). We evaluated differences among proportions and means using the Fisher’s exact test and ANOVA, respectively. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) of the risk of placental injury according to pregnancy complication groups were estimated by means unadjusted and adjusted logistic regression models. The adjusted models also included terms for maternal age (years, in continuous), pre-pregnancy BMI (kg/m2, in continuous), smoking status (never vs. current during pregnancy), gestational age at delivery (weeks, in continuous), soluble fms-like tirosin-kinasi 1 to placental growth factor ratio (in continuous), placental weight (g, in continuous), and placental area (cm2, in continuous). All statistical tests were two-sided with a significance level set at <0.05. All analyses were conducted using R version 4.0.5. (R Core Team, 2021)

3. Results

About 600 women come to our institution for high-risk antenatal care each year. The study was conducted from 1st May 2019 to 31st December 2021. In this period of time, out of 1876 single pregnancies evaluated in our clinics, a total of 72 (3.8%) patients met the inclusion criteria and agreed to participate in the study. At the same time, 16 uneventful pregnancies were recruited as controls, for a total of 88 participants.
We divided patients into five groups according to maternal and fetal characteristics: (1) n = 10 pregnancies complicated by HDP and associated with AGA fetus (HDP-AGA fetus); (2) n = 26 pregnancies complicated by HDP and associated with FGR (HDP-FGR); (3) n = 12 normotensive patients with early (gestational age ≤ 32 weeks) FGR (early FGR); (4) n = 24 normotensive patients with late (gestational age > 32 weeks) FGR (late FGR); and (5) n = 16 uneventful control pregnancies. Table 1 reports maternal, obstetric, and neonatal characteristics according to pregnancy complication groups and controls.
Table 2 shows biophysical and biochemical markers.
The early FGR group reported significantly higher uterine pulsatility index (1.62 ± 0.54; p < 0.01) and umbilical artery pulsatility index (1.73 ± 0.33; p < 0.01) compared to others groups. Conversely, the early FGR group had a significantly lower cerebral placental ratio (0.93 ± 0.27; p < 0.01). The HDP-FGR group showed significantly higher level of sFlt-1 (8916.52 ± 7500.87 pg/ML; p < 0.01) and significantly lower level of PlGF (39.35 ± 50.62 pg/ML; p < 0.01). According to previous results, the ratio between sFlt-1 and PlGF was significantly higher (584.37 ± 798.73) in the HDP-FGR group.
Table 3 reports placental characteristics according to Amsterdam classification system of placental pathology.
The early FGR group showed a significantly lower placental weight (214 ± 84 g; p < 0.01) and area (409 ± 142 cm2; p < 0.01) compared to all other groups. The maternal vascular malperfusion was significantly higher in the HDP-FGR group (92%; p < 0.01). This result was mainly driven by placental infarction, distal villous hypoplasia, and decidual arteriopathy. The late FGR group showed higher proportion of delayed villous maturation (83%; p = 0.01). Of interest, this high proportion was significantly different from what was observed in early FGR.
Table 4 reports the ORs and 95% CIs of the risk of placental lesions according to pregnancy complication groups and controls.
The unadjusted models showed a significantly higher risk of vascular maternal malperfusion for the HDP-FGR group (OR = 20.00; 95% CI: 4.03–155.90) and for early FGR group (OR = 8.33; 95% CI: 1.55–67.77) than controls. The adjusted model showed a significantly higher risk for HDP-FGR group (OR = 54.94; 95% CI: 2.90–2902.41). The risk of delayed villous maturation was significantly higher in the late FGR group compared to controls in both unadjusted (OR = 8.33; 95% CI: 2.04–40.73) and adjusted (OR = 21.64; 95% CI: 3.54–171.87) analyses. The HDP-FGR group showed a higher risk of delayed villous maturation in the adjusted analyses (OR = 16.83; 95% CI: 1.85–204.44).

4. Discussion

Our findings suggest that maternal vascular malperfusion of the placental bed affected more than half pregnant women in every groups, but it was significantly more observed in placenta of pregnant women affected by HDP-FGR (92%) and early-FGR (83%) than in HDP-AGA fetus (60%), late FGR (63%), and even uneventful control pregnancies (38%). These two groups also showed significantly higher values of the uterine and umbilical arteries Doppler velocimetry and of the sFlt-1/PLGF ratio, the latter being a marker of the oxidative stress of the syncytiotrophoblast.
These findings demonstrate that the severe complications that these pregnancies develop both on the fetal side (fetal growth restriction) and then on the maternal side (hypertension) are a consequence of an early shallow trophoblastic invasion, poor placental development, poor fetal nutrition, and eventually placental oxidative stress. As expected, pregnancies affected by HDP-FGR had the worst obstetric outcome with the lowest gestational age at delivery and the highest incidence of cesarean sections and neonatal deaths.
Opposite to these findings, lesions consistent with delayed villous maturation were significantly more common in women with pregnancies complicated by late FGR (83%).
The decidual arteriopathy was found with a significant prevalence both in all women with hypertensive disorders and in those with early and late FGR but was observed only in one case of the 16 uneventful pregnancies.
Our data show that maternal and fetal vascular malperfusion of the placenta are not mutually exclusive. Placental developmental biology is a complex phenomenon during which different insults might produce overlapping histological lesions, and the same disease might also produce different severity and timeframe of occurrence of the same adverse clinical outcome.
However, the different prevalence of maternal vascular malperfusion in placenta of pregnancies affected by hypertensive disorders and FGR is in agreement with previous reported pathological [30,31,32,33,34,35] and clinical findings that eventually support the different etiology of the main phenotypes of hypertensive disorders of pregnancy [3].
In agreement with previously reported data, our results show a significant association between the presence of lesion of maternal vascular malperfusion and abnormal Doppler velocimetry [34,35,36]. Of interest, an abnormal uterine PI, which is a proxy of reduced uterine blood flow volume [37], was also significantly associated with decidual arteriopathy. The abnormal uterine blood flow and the malperfusion of the placental bed might enhance oxidative stress damage, inducing additional placental hypo-perfusion, resulting in turn to distal villous hypoplasia and infarction [38], as observed in our cases. Indeed, the by-products of oxidative stress of the syncytiotrophoblast generate an abnormal concentration PlGF and sFlt-1 and reverberate on the maternal endothelium, causing vasoconstriction and maternal hypertension [39].
The late FGR group has a relatively good obstetric and neonatal outcome with an adequate gestational period for delivery, a small number of caesarean sections, and no neonatal deaths. In these cases, the placental lesions consistent mainly with delayed villous maturation (83%). This type of histological lesion of the placenta represents a “maldevelopment” of the villous tree. According to the Amsterdam criteria [10], delayed villous maturation exhibits monotonous villous population with reduced numbers of vasculosyncytial membranes for the gestational age as well as a continuous cytotrophoblast layer and centrally placed capillaries. This finding appears late in pregnancy [10]. The delayed occurrence of villous maturation might be related to a hypoxic-oxidative environment that manifests late in pregnancy, likely when placental growth reaches its functional limits [40]. However, the severity of these late maldevelopments is not enough to produce high values of sFlt-1/PlGF ratio, a marker of oxidative stress.
Many preventive strategies have been proposed for the prevention of these pregnancy complications, such as angiogenic factors, nitric oxide (NO) and L-arginine supplementation, endothelial stressor inhibitors, H2S donors, statins, and antioxidants [41]. However, so far, the only preventive intervention supported by robust evidence is the administration of low-dose aspirin since early gestion in women who proved at risk of preeclampsia at the first-trimester screening [42].
However, this preventive strategy is poorly effective in HDP occurring late in gestation and frequently associated with normally grown fetuses or late FGR [43]. This limitation is likely to be the consequence of the assumption that HDP and preeclampsia are not a syndrome and that one preventive intervention fits for all phenotypes. Indeed, “maternal syndrome preeclampsia”, as associated with obesity and metabolic syndrome, is now acknowledged as one of the main causative risk factors and predisposing conditions for hypertensive disorders of pregnancy [44].
If obesity and metabolic syndrome is the villain of HDP with normally grown fetuses and late IUGR, and low-dose aspirin is partially ineffective to prevent this condition, then a different preventive measure might be enforced in these pregnant women.
Growing evidence has shown the positive effects of the Mediterranean diet (MD) on health outcomes (i.e., lower incidence of cardiovascular and metabolic diseases, lower incidence of neurodegenerative diseases, lower incidence of multiple cancer sites, and lower mortality) [23,24,25,26,45]. The traditional Mediterranean diet is a plant-oriented dietary pattern characterized by a high intake of vegetables, fruit, whole grains, legumes, and nuts; a moderate intake of dairy products (mostly cheese and yoghurt); a moderate intake of fish and poultry; a low intake of red meat; a high intake of extra-virgin olive oils, used as the main source of fat; and a moderate intake of wine, consumed with meals [46]. Maternal adherence to MD may play a role in placental development and function formation. Indeed, B vitamins act as substrates in different cellular pathways and play a role as cofactors in events such as cell multiplication, apoptosis, and intracellular signaling, all of which can target oxidative damage [47,48]. These processes are also affected by saturated fats, trans fatty acids, and cholesterol [49]. For this reason, the adherence to a diet rich in B vitamins and monounsaturated and polyunsaturated fats may positively affect the placenta and pregnancy outcome [25,50]. In addition, a diet rich in vegetables, fruits, poultry, and fish was associated with a 25% reduction in the risk of FGR [51].
Furthermore, pregnant women who had a low adherence to the MD showed smaller placentas and with a greater vascular resistance than pregnant women who highly adhered to the MD [52,53]. The placentation of women with low MD adherence was characterized by pathological vascular remodeling, increased inflammation, oxidative stress, and rapid cell division that caused similar lesions as described in our study [52,53,54].
Moreover, the MD reduces the circulation of inflammatory markers and endothelial dysfunction, such as C-reactive protein and E-selectin [55,56,57].
Finally, recent epigenetic studies have investigated the role of MD in the early stages of embryonic growth, demonstrating how correct nutrition plays a fundamental role already in the periconceptional period [58].
One of the strengths of this study is that we rigorously met the criteria for blinded placental pathology examination by applying a systematic and rigorous approach to classify placental characteristics, based on an international consensus. This approach avoids the limitations on local policies and definitions. The consecutive recruitment foreseen according to the design of the study was partially interrupted by the first two waves of the COVID-19 pandemic, when our high-risk maternity was designed as the main regional hub in Lombardy for SARS-COV-2 infections. Furthermore, our controls and cases are not matched for gestational age at delivery. This aspect should be further investigated, but as such, this would introduce further limitations due to the different etiology of premature delivery that, obviously, could not be considered as “normal” controls. A small sample of patients and the lack of information on patients by patient dietary status are also additional limiting factors of the study.
In conclusion, this study suggests a similar, significantly higher prevalence of placental maternal vascular malperfusion in HDP-FGR and early FGR. This might imply a common etiology. Conversely, HDP-AGA fetus, which includes preeclampsia not associated with FGR, and late FGR represent a more heterogeneous condition mainly but not always characterized by abnormal villous tree development and maturation. The different prevalence of patterns of placental lesions were coherently associated with indices of feto-placental Doppler interrogation and sFlt-1/PlGF ratio. These conditions are likely associated with different etiologies, such as maternal pre-pregnancy risk factors for metabolic syndrome. These findings suggest a possible preventive nutritional approach in addition to low-dose aspirin for pregnant women with predisposing factors for HDP-AGA fetuses and late FGR.

Author Contributions

Conceptualization, D.D.D. and E.F.; methodology, E.F.; software, A.F. and M.D.; validation, E.F., D.D.D. and L.A.; formal analysis, M.D., investigation, F.F., M.P. and V.S.; resources T.S., G.P.B. and S.Z.; data curation, M.D.; writing—original draft D.D.D. and L.A.; writing—review and editing, F.D.; visualization, L.A., F.D. and M.D.; supervision, E.F. and F.D.; project administration, E.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The Ethical Committee approved the study (EC NN Milano 10818, December 2018).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data that support the findings of this study are available from the first author (D.D.D.) upon reasonable request.

Acknowledgments

This study was supported by a grant from A.S.M., Charity, and partially supported by the CURE-Charity for research in prenatal medicine.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bokslag, A.; van Weissenbruch, M.; Mol, B.W.; de Groot, C.J. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum. Dev. 2016, 102, 47–50. [Google Scholar] [CrossRef]
  2. Myatt, L.; Redman, C.W.; Staff, A.C.; Hansson, S.; Wilson, M.; Laivuori, H.; Poston, L.; Roberts, J.M.; Global Pregnancy CoLaboratory. Strategy for Standardization of Preeclampsia Research Study Design. Hypertension 2014, 63, 1293–1301. [Google Scholar] [CrossRef] [Green Version]
  3. Burton, G.J.; Redman, C.W.; Roberts, J.M.; Moffett, A. Pre-eclampsia: Pathophysiology and clinical implications. BMJ 2019, 15, 366. [Google Scholar] [CrossRef] [Green Version]
  4. Redman, C.W.; Staff, A.C. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am. J. Obstet. Gynecol. 2015, 213, S9.e1–S9.e4. [Google Scholar] [CrossRef]
  5. Hung, T.-H.; Skepper, J.N.; Burton, G.J. In Vitro Ischemia-Reperfusion Injury in Term Human Placenta as a Model for Oxidative Stress in Pathological Pregnancies. Am. J. Pathol. 2001, 159, 1031–1043. [Google Scholar] [CrossRef] [Green Version]
  6. Jauniaux, E.; Watson, A.L.; Hempstock, J.; Bao, Y.-P.; Skepper, J.N.; Burton, G.J. Onset of Maternal Arterial Blood Flow and Placental Oxidative Stress: A Possible Factor in Human Early Pregnancy Failure. Am. J. Pathol. 2000, 157, 2111–2122. [Google Scholar] [CrossRef]
  7. Pereira, R.D.; De Long, N.E.; Wang, R.C.; Yazdi, F.T.; Holloway, A.C.; Raha, S. Angiogenesis in the Placenta: The Role of Reactive Oxygen Species Signaling. BioMed Res. Int. 2015, 2015, 814543. [Google Scholar] [CrossRef] [Green Version]
  8. Cuffe, J.S.; Holland, O.; Salomon, C.; Rice, G.E.; Perkins, A.V. Review: Placental derived biomarkers of pregnancy disorders. Placenta 2017, 54, 104–110. [Google Scholar] [CrossRef] [Green Version]
  9. Stanek, J. Chorangiosis of Chorionic Villi: What Does It Really Mean? Arch. Pathol. Lab. Med. 2016, 140, 588–593. [Google Scholar] [CrossRef] [Green Version]
  10. Khong, T.Y.; Mooney, E.E.; Ariel, I.; Balmus, N.C.M.; Boyd, T.K.; Brundler, M.-A.; Derricott, H.; Evans, M.J.; Faye-Petersen, O.M.; Gillan, J.E.; et al. Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch. Pathol. Lab. Med. 2016, 140, 698–713. [Google Scholar] [CrossRef] [Green Version]
  11. Hempstock, J.; Jauniaux, E.; Greenwold, N.; Burton, G.J. The contribution of placental oxidative stress to early pregnancy failure. Hum. Pathol. 2003, 34, 1265–1275. [Google Scholar] [CrossRef]
  12. Aris, A.; Benali, S.; Ouellet, A.; Moutquin, J.; Leblanc, S. Potential Biomarkers of Preeclampsia: Inverse Correlation between Hydrogen Peroxide and Nitric Oxide Early in Maternal Circulation and at Term in Placenta of Women with Preeclampsia. Placenta 2009, 30, 342–347. [Google Scholar] [CrossRef]
  13. Melchiorre, K.; Thilaganathan, B. Maternal cardiac function in preeclampsia. Curr. Opin. Obstet. Gynecol. 2011, 23, 440–447. [Google Scholar] [CrossRef]
  14. Tay, J.; Foo, L.; Masini, G.; Bennett, P.R.; McEniery, C.M.; Wilkinson, I.B.; Lees, C.C. Early and late preeclampsia are characterized by high cardiac output, but in the presence of fetal growth restriction, cardiac output is low: Insights from a prospective study. Am. J. Obstet. Gynecol. 2018, 218, 517.e1–517.e12. [Google Scholar] [CrossRef]
  15. Ferrazzi, E.; Zullino, S.; Stampalija, T.; Vener, C.; Cavoretto, P.; Gervasi, M.T.; Vergani, P.; Mecacci, F.; Marozio, L.; Oggè, G.; et al. Bedside diagnosis of two major clinical phenotypes of hypertensive disorders of pregnancy. Ultrasound Obstet. Gynecol. 2015, 48, 224–231. [Google Scholar] [CrossRef] [Green Version]
  16. Magee, L.A.; Pels, A.; Helewa, M.; Rey, E.; von Dadelszen, P.; Audibert, F.; Bujold, E.; Côté, A.-M.; Douglas, M.J.; Eastabrook, G.; et al. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary. J. Obstet. Gynaecol. Can. 2014, 36, 416–438. [Google Scholar] [CrossRef]
  17. Egbor, M.; Ansari, T.; Morris, N.; Green, C.; Sibbons, P. Maternal medicine: Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG Int. J. Obstet. Gynaecol. 2006, 113, 580–589. [Google Scholar] [CrossRef]
  18. Orabona, R.; Donzelli, C.M.; Falchetti, M.; Santoro, A.; Valcamonico, A.; Frusca, T. Placental histological patterns and uterine artery Doppler velocimetry in pregnancies complicated by early or late pre-eclampsia. Ultrasound Obstet. Gynecol. 2016, 47, 580–585. [Google Scholar] [CrossRef]
  19. Redman, C.W.; Sargent, I.L.; Staff, A.C. IFPA Senior Award Lecture: Making sense of pre-eclampsia—Two placental causes of preeclampsia? Placenta 2014, 35, S20–S25. [Google Scholar] [CrossRef]
  20. Brosens, I.; Pijnenborg, R.; Vercruysse, L.; Romero, R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am. J. Obstet. Gynecol. 2011, 204, 193–201. [Google Scholar] [CrossRef] [Green Version]
  21. Mifsud, W.; Sebire, N.J. Placental Pathology in Early-Onset and Late-Onset Fetal Growth Restriction. Fetal Diagn. Ther. 2014, 36, 117–128. [Google Scholar] [CrossRef] [PubMed]
  22. Staff, A.; Redman, C. IFPA Award in Placentology Lecture: Preeclampsia, the decidual battleground and future maternal cardiovascular disease. Placenta 2014, 35, S26–S31. [Google Scholar] [CrossRef] [PubMed]
  23. Miranda, J.; Simões, R.V.; Paules, C.; Cañueto, D.; Pardo-Cea, M.A.; García-Martín, M.L.; Crovetto, F.; Fuertes-Martin, R.; Domenech, M.; Gómez-Roig, M.D.; et al. Metabolic profiling and targeted lipidomics reveals a disturbed lipid profile in mothers and fetuses with intrauterine growth restriction. Sci. Rep. 2018, 8, 13614. [Google Scholar] [CrossRef] [PubMed]
  24. Chatzi, L.; Mendez, M.; Garcia, R.; Roumeliotaki, T.; Ibarluzea, J.; Tardon, A.; Amiano, P.; Lertxundi, A.; Iñiguez, C.; Vioque, J.; et al. Mediterranean diet adherence during pregnancy and fetal growth: INMA (Spain) and RHEA (Greece) mother–child cohort studies. Br. J. Nutr. 2012, 107, 135–145. [Google Scholar] [CrossRef] [PubMed]
  25. Timmermans, S.; Steegers-Theunissen, R.P.; Vujkovic, M.; den Breeijen, H.; Russcher, H.; Lindemans, J.; MacKenbach, J.; Hofman, A.; Lesaffre, E.E.; Jaddoe, V.V.; et al. The Mediterranean diet and fetal size parameters: The Generation R Study. Br. J. Nutr. 2012, 108, 1399–1409. [Google Scholar] [CrossRef] [Green Version]
  26. Crovetto, F.; Crispi, F.; Borras, R.; Paules, C.; Casas, R.; Martín-Asuero, A.; Arranz, A.; Vieta, E.; Estruch, R.; Gratacós, E. Mediterranean diet, Mindfulness-Based Stress Reduction and usual care during pregnancy for reducing fetal growth restriction and adverse perinatal outcomes: IMPACT BCN (Improving Mothers for a better PrenAtal Care Trial BarCeloNa): A study protocol for a randomized controlled trial. Trials 2021, 22, 362. [Google Scholar] [CrossRef]
  27. Menard, M.K.; Kilpatrick, S.; Saade, G.; Hollier, L.M.; Joseph, G.F., Jr.; Barfield, W.; Callaghan, W.; Jennings, J.; Conry, J. American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine with the assistance of. ACOG/SMFM obstetric care consensus: Levels of maternal care. Obstet. Gynecol. 2015, 125, 502–515. [Google Scholar]
  28. Robinson, H.P.; Fleming, J.E.E. A critical evaluation of sonar “crown-rump length” measurements. BJOG Int. J. Obstet. Gynaecol. 1975, 82, 702–710. [Google Scholar] [CrossRef]
  29. Gordijn, S.J.; Beune, I.M.; Thilaganathan, B.; Papageorghiou, A.; Baschat, A.A.; Baker, P.N.; Silver, R.M.; Wynia, K.; Ganzevoort, W. Consensus definition of fetal growth restriction: A Delphi procedure. Ultrasound Obstet. Gynecol. 2016, 48, 333–339. [Google Scholar] [CrossRef]
  30. Burton, G.; Woods, A.; Jauniaux, E.; Kingdom, J. Rheological and Physiological Consequences of Conversion of the Maternal Spiral Arteries for Uteroplacental Blood Flow during Human Pregnancy. Placenta 2009, 30, 473–482. [Google Scholar] [CrossRef] [Green Version]
  31. Jauniaux, E.; Hempstock, J.; Greenwold, N.; Burton, G.J. Trophoblastic Oxidative Stress in Relation to Temporal and Regional Differences in Maternal Placental Blood Flow in Normal and Abnormal Early Pregnancies. Am. J. Pathol. 2003, 162, 115–125. [Google Scholar] [CrossRef] [Green Version]
  32. Khong, T.Y.; DE Wolf, F.; Robertson, W.B.; Brosens, I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. BJOG Int. J. Obstet. Gynaecol. 1986, 93, 1049–1059. [Google Scholar] [CrossRef] [PubMed]
  33. Paules, C.; Youssef, L.; Rovira, C.; Crovetto, F.; Nadal, A.; Peguero, A.; Figueras, F.; Eixarch, E.; Crispi, F.; Miranda, J.; et al. Distinctive patterns of placental lesions in pre-eclampsia vs small-for-gestational age and their association with fetoplacental Doppler. Ultrasound Obstet. Gynecol. 2019, 54, 609–616. [Google Scholar] [CrossRef] [PubMed]
  34. Ferrazzi, E.; Bulfamante, G.; Mezzopane, R.; Barberà, A.; Ghidini, A.; Pardi, G. Uterine Doppler Velocimetry and Placental Hypoxic-ischemic Lesion in Pregnancies with Fetal Intrauterine Growth Restriction. Placenta 1999, 20, 389–394. [Google Scholar] [CrossRef]
  35. Parra-Saavedra, M.; Crovetto, F.; Triunfo, S.; Savchev, S.; Peguero, A.; Nadal, A.; Gratacós, E.; Figueras, F. Association of Doppler parameters with placental signs of underperfusion in late-onset small-for-gestational-age pregnancies. Ultrasound Obstet. Gynecol. 2014, 44, 330–337. [Google Scholar] [CrossRef]
  36. Ferrazzi, E.; Rigano, S.; Padoan, A.; Boito, S.; Pennati, G.; Galan, H. Uterine artery blood flow volume in pregnant women with an abnormal pulsatility index of the uterine arteries delivering normal or intrauterine growth restricted newborns. Placenta 2011, 32, 487–492. [Google Scholar] [CrossRef]
  37. Kingdom, J.; Huppertz, B.; Seaward, G.; Kaufmann, P. Development of the placental villous tree and its consequences for fetal growth. Eur. J. Obstet. Gynecol. Reprod. Biol. 2000, 92, 35–43. [Google Scholar] [CrossRef]
  38. Falco, M.L.; Sivanathan, J.; Laoreti, A.; Thilaganathan, B.; Khalil, A. Placental histopathology associated with pre-eclampsia: Systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2017, 50, 295–301. [Google Scholar] [CrossRef]
  39. Schoots, M.H.; Bourgonje, M.F.; Bourgonje, A.R.; Prins, J.R.; van Hoorn, E.G.; Abdulle, A.E.; Kobold, A.C.M.; van der Heide, M.; Hillebrands, J.-L.; van Goor, H.; et al. Oxidative stress biomarkers in fetal growth restriction with and without preeclampsia. Placenta 2021, 115, 87–96. [Google Scholar] [CrossRef]
  40. Kwiatkowski, S.; Dołęgowska, B.; Kwiatkowska, E.; Rzepka, R.; Marczuk, N.; Loj, B.; Mikolajek-Bedner, W.; Torbe, A. Do the physiological aging of the placenta and the changes in angiogenesis marker sFlt-1 and PlGF concentrations predispose patients to late-onset preeclampsia? J. Matern. Fetal Neonatal Med. 2019, 32, 11–20. [Google Scholar] [CrossRef]
  41. Cindrova-Davies, T. The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. Front. Pharmacol. 2014, 5, 119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Poon, L.C.; Shennan, A.; Hyett, J.A.; Kapur, A.; Hadar, E.; Divakar, H.; McAuliffe, F.; da Silva Costa, F.; von Dadelszen, P.; McIntyre, H.D.; et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet. 2019, 145 (Suppl. S1), 1–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Rolnik, D.L.; Wright, D.; Poon, L.C.; O’Gorman, N.; Syngelaki, A.; de Paco Matallana, C.; Akolekar, R.; Cicero, S.; Janga, D.; Singh, M.; et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N. Engl. J. Med. 2017, 17, 613–622. [Google Scholar] [CrossRef] [PubMed]
  44. Redman, C.W.G.; Staff, A.C.; Roberts, J.M. Syncytiotrophoblast stress in preeclampsia: The convergence point for multiple pathways. Am. J. Obstet. Gynecol. 2022, 226, S907–S927. [Google Scholar] [CrossRef]
  45. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.-I.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J.; et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N. Engl. J. Med. 2018, 378, e34. [Google Scholar] [CrossRef]
  46. Balder, H.F.; Virtanen, M.; Brants, H.A.M.; Krogh, V.; Dixon, L.B.; Tan, F.; Mannisto, S.; Bellocco, R.; Pietinen, P.; Wolk, A.; et al. Common and Country-Specific Dietary Patterns in Four European Cohort Studies. J. Nutr. 2003, 133, 4246–4251. [Google Scholar] [CrossRef] [Green Version]
  47. Gao, X.; Yao, M.; McCrory, M.A.; Ma, G.; Li, Y.; Roberts, S.B.; Tucker, K.L. Dietary Pattern Is Associated with Homocysteine and B Vitamin Status in an Urban Chinese Population. J. Nutr. 2003, 133, 3636–3642. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Tamura, T.; Picciano, M.F. Folate and human reproduction. Am. J. Clin. Nutr. 2006, 83, 993–1016. [Google Scholar] [CrossRef]
  49. Larqué, E.; Zamora, S.; Gil, A. Dietary trans fatty acids in early life: A review. Early Hum. Dev. 2001, 65, S31–S41. [Google Scholar] [CrossRef]
  50. Costanza, J.; Camanni, M.; Ferrari, M.M.; De Cosmi, V.; Tabano, S.; Fontana, L.; Radaelli, T.; Privitera, G.; Alberico, D.; Colapietro, P.; et al. Assessment of pregnancy dietary intake and association with maternal and neonatal outcomes. Pediatr. Res. 2022, 91, 1890–1896. [Google Scholar] [CrossRef]
  51. Knudsen, V.K.; Orozova-Bekkevold, I.; Mikkelsen, T.B.; Wolff, S.; Olsen, S. Major dietary patterns in pregnancy and fetal growth. Eur. J. Clin. Nutr. 2008, 62, 463–470. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Bleker, O.; Buimer, M.; Van Der Post, J.; Van Der Veen, F. Ted (G.J.) Kloosterman: On Intrauterine Growth. The Significance of Prenatal Care. Studies on Birth Weight, Placental Weight and Placental Index. Placenta 2006, 27, 1052–1054. [Google Scholar] [CrossRef] [PubMed]
  53. Goodger, A.M.; Rogers, P.A.W. Uterine endothelial cell proliferation before and after embryo implantation in rats. Reproduction 1993, 99, 451–457. [Google Scholar] [CrossRef]
  54. Burton, G.J.; Jaunaiux, E. Maternal vascularisation of the human placenta: Does the embryo develop in a hypoxic environment? Gynecol. Obs. Fertil. 2001, 29, 503–508. [Google Scholar] [CrossRef]
  55. Nettleton, J.A.; Steffen, L.M.; Mayer-Davis, E.J.; Jenny, N.S.; Jiang, R.; Herrington, D.M.; Jacobs, D.R. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Clin. Nutr. 2006, 83, 1369–1379. [Google Scholar] [CrossRef]
  56. Esposito, K.; Marfella, R.; Ciotola, M.; Di Palo, C.; Giugliano, F.; Giugliano, G.; D’Armiento, M.; D’Andrea, F.; Giugliano, D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. JAMA 2004, 22, 1440–1446. [Google Scholar] [CrossRef] [Green Version]
  57. Du, H.; van der A, D.L.; van Bakel, M.M.; van der Kallen, C.J.; Blaak, E.E.; van Greevenbroek, M.M.; Jansen, E.H.; Nijpels, G.; Stehouwer, C.D.; Dekker, J.M.; et al. Glycemic index and glycemic load in relation to food and nutrient intake and metabolic risk factors in a Dutch population. Am. J. Clin. Nutr. 2008, 87, 655–661. [Google Scholar] [CrossRef] [Green Version]
  58. Steegers-Theunissen, R.P.; Obermann-Borst, S.A.; Kremer, D.; Lindemans, J.; Siebel, C.; Steegers, E.A.; Slagboom, P.E.; Heijmans, B.T. Periconceptional maternal folic acid use of 400 microg per day is related to increased methylation of the IGF2 gene in the very young child. PLoS ONE 2009, 16, e7845. [Google Scholar]
Table
Table 1. Maternal, obstetric, and neonatal characteristics a according to pregnancy complication groups and controls.
Table 1. Maternal, obstetric, and neonatal characteristics a according to pregnancy complication groups and controls.
VariablePregnancy Complication Group p-Value
HDP-AGA Fetus
(n = 10)		HDP-FGR
(n = 26)		Early FGR
(n = 12)		Late FGR
(n = 24)		Controls
(n = 16)
Maternal characteristics
Gestational age at recruitment (weeks)36.8 ± 2.431.1 ± 3.928.0 ± 3.634.1 ± 4.132.7 ± 5.0p < 0.01 b
Age (years)34 ± 434 ± 633 ± 630 ± 635 ± 3p = 0.13 b
Pre-pregnancy BMI (kg/m2)25.9 ± 4.924.5 ± 5.822.1 ± 3.321.7 ± 3.222.3 ± 3.8p = 0.05 b
Smoking status during pregnancy0 (0)1 (4)4 (33)4 (17)0 (0)p = 0.02 c
Family history of hypertension 7 (70)16 (62)5 (42)14 (58)10 (63)p = 0.74 c
Nulliparous women8 (80)19 (73)5 (42)18 (75)11 (69)p = 0.29 c
Obstetric characteristics
Gestational age at delivery (weeks)38.0 ± 2.432.8 ± 3.933.2 ± 3.938.5 ± 1.840.0 ± 1.3p < 0.01 b
Obstetric history, previous HDP or FGR2 (20)5 (19)3 (25)1 (4)0 (0)p = 0.08 c
Caesarean section5 (50)25 (96)10 (83)5 (21)2 (13)p < 0.01 c
Neonatal characteristics
Neonatal weight percentile54 ± 306 ± 32 ± 35 ± 349 ± 18p < 0.01 b
NICU admission d1 (10)17 (65)9 (75)3 (13)0 (0)p < 0.01 c
Perinatal morbidity1 (10)12 (46) 8 (67)1 (4)0 (0)p < 0.01 c
Neonatal death0 (0.0)4 e (15)1 f (8)0 (0.0)0 (0)p = 0.11 c
Time recruitment-to-delivery (weeks)1.2 ± 1.21.8 ± 2.35.2 ± 2.74.5 ± 3.77.3 ± 5.2p < 0.01
a Continuous variables are expressed as mean ± standard deviation, and categorical variables are expressed as absolute frequencies and percentages in parenthesis; b calculated by means of ANOVA test; c calculated by means of Fisher’s exact test; d one missing value in the HDP-FGR group and in the early FGR group, respectively; e three perinatal deaths and one intrauterine fetal death; f medical termination of pregnancy. Abbreviations: BMI, body mass index; FGR, intrauterine growth restriction; HDP, hypertensive disorders of pregnancy; NICU, neonatal intensive care unit. Gestational age at recruitment was significantly lower in the early FGR group (mean ± SD: 28.0 ± 4.1 weeks; p < 0.01) compared to other groups. Women belonging to HDP-AGA fetus group had a significantly higher pre-pregnancy BMI (25.9 ± 4.9 kg/m2; p = 0.05), whereas women in the early FGR group were more likely to be smokers during pregnancy (33.3%) than women of other groups. Women in the HDP-FGR group had a significantly lower gestational age at delivery (32.8 ± 3.9 weeks; p < 0.01) and a significantly higher proportion of caesarean section (96.2%; p < 0.01). Neonatal weight percentile was significantly lower in the early FGR group (2 ± 3; p < 0.01). In addition, the early FGR group showed significantly higher proportion of NICU admission (75.0%; p < 0.01) and perinatal morbidity (66.7%; p < 0.01). No significant difference emerged for the other maternal, obstetric, and neonatal characteristic considered.
Table
Table 2. Biophysical and biochemical markers a according to pregnancy complication groups and controls.
Table 2. Biophysical and biochemical markers a according to pregnancy complication groups and controls.
VariablePregnancy Complication Group p-Value
HDP-AGA Fetus
(n = 10)		HDP-FGR
(n = 26)		Early FGR
(n = 12)		Late FGR
(n = 24)		Controls
(n = 16)
Biophysical marker
Uterine pulsatility index0.74 ± 0.301.32 ± 0.391.62 ± 0.540.75 ± 0.220.70 ± 0.21p < 0.01 b
Umbilical artery pulsatility index0.89 ± 0.161.33 ± 0.481.73 ± 0.330.95 ± 0.180.92 ± 0.15p < 0.01 b
Middle cerebral artery pulsatility index c1.75 ± 0.271.66 ± 0.641.57 ± 0.421.74 ± 0.411.82 ± 0.39p = 0.69 b
Cerebral placental ratio c2.06 ± 0.581.39 ± 0.620.93 ± 0.271.84 ± 0.341.99 ± 0.47p < 0.01 b
Biochemical marker
Soluble fms-like tirosin-kinasi 1 (pg/ML) d5872 ± 37558916 ± 75004282 ± 36933247 ± 23452020 ± 1104p < 0.01 b
Placental growth factor (pg/ML) e60 ± 3739 ± 51155 ± 267230 ± 261498 ± 438p < 0.01 b
Soluble fms-like tirosin-kinasi 1 to placental growth factor ratio f187 ± 341584 ± 799129 ± 18033 ± 3925 ± 60p < 0.01 b
a Expressed as mean ± standard deviation; b calculated by means of ANOVA test; c one missing value in controls; d two missing values in controls, one missing value in the HDP-AGA fetus group, and three missing values in the HDP-FGR group; e one missing value in the HDP-AGA fetus group, three missing values in the HDP-FGR group, and one missing value in the early FGR group; f two missing values in controls, one missing value in the HDP-AGA fetus group, two missing values in the HDP-FGR group, and one missing value in the early FGR group.
Table
Table 3. Placental characteristics a and Amsterdam classification system of placental injury according to pregnancy complication groups and controls.
Table 3. Placental characteristics a and Amsterdam classification system of placental injury according to pregnancy complication groups and controls.
VariablePregnancy Complication Group p-Value
HDP-AGA Fetus
(n = 10)		HDP-FGR
(n = 26)		Early FGR
(n = 12)		Late FGR
(n = 24)		Controls
(n = 16)
Placental characteristics
Placental weight (g) b512 ± 116269 ± 114214 ± 84411 ± 70502 ± 54p < 0.01 c
Placental area (cm2)968 ± 320505 ± 175409 ± 142745 ± 306870 ± 165p < 0.01 c
Feto-placental ratio b6.0 ± 0.75.5 ± 2.76.0 ± 1.26.3 ± 1.16.6 ± 0.6p = 0.27
Amsterdam classification system
Maternal vascular malperfusion6 (60)24 (92)10 (83)15 (63)6 (38)p < 0.01 d
Placental infarction3 (30)12 (46)3 (25)8 (33)0 (0)p = 0.01 d
Retroplacental hemorrhage0 (0)4 (15)2 (17)1 (4)0 (0)p = 0.24 d
Distal villous hypoplasia0 (0)11 (42)2 (17)3 (13)1 (6)p = 0.01 d
Accelerated villous maturation5 (50)15 (58)5 (42)9 (38)4 (25)p = 0.30 d
Decidual arteriopathy3 (30)11 (42)8 (67)5 (21)1 (6)p < 0.01 d
Fetal vascular malperfusion0 (0)3 (12)1 (8)0 (0)0 (0)p = 0.24 d
Delayed villous maturation4 (40)13 (50)5 (42)20 (83)6 (38)p = 0.01 d
Villitis of unknown etiology e0 (0)4 (15)2 (17)0 (0)2 (13)p = 0.23 d
Ascending Intrauterine Infection2 (20)7 (27)5 (42)4 (17)3 (19)p = 0.55 d
a Expressed as mean ± standard deviation; b one missing value in the late FGR group; c calculated by means of ANOVA test; d calculated by means of Fisher’s exact test; e two missing values in the HDP-FGR group, and one missing value in the late FGR group.
Table
Table 4. Odds ratios (OR) and corresponding 95% confidence intervals (CI) of the risk of placental injury (defined by Amsterdam classification system) according to pregnancy complication groups.
Table 4. Odds ratios (OR) and corresponding 95% confidence intervals (CI) of the risk of placental injury (defined by Amsterdam classification system) according to pregnancy complication groups.
Pregnancy Complication
Group		Placental Injury According to Amsterdam Classification System
Maternal Vascular
Malperfusion		Fetal Vascular
Malperfusion		Delayed Villous
Maturation		Villitis of Unknown
Etiology		Ascending Intrauterine Infection
OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
Unadjusted model
ControlsRef.Not applicableRef.Not applicableRef.
HDP-AGA fetus2.50 (0.51–13.64)1.11 (0.21–5.68)1.08 (0.12–8.00)
HDP-FGR20.00 (4.03–155.90)1.67 (0.47–6.20)1.60 (0.37–8.47)
Early FGR8.33 (1.55–67.77)1.19 (0.25–5.61)3.10 (0.58–19.09)
Late FGR2.78 (0.77–10.80)8.33 (2.04–40.73)0.87 (0.16–5.00)
Adjusted modela
ControlsRef.Not applicableRef.Not applicableRef.
HDP-AGA fetus5.27 (0.66–50.94)2.80 (0.36–21.97)1.93 (0.17–20.27)
HDP-FGR54.94 (2.90–2902.41)16.83 (1.85–204.44)6.31 (0.58–83.89)
Early FGR6.54 (0.29–191.19)7.54 (0.57–114.87)5.06 (0.31–93.57)
Late FGR2.45 (0.43–14.90)21.64 (3.54–171.87)0.88 (0.11–6.96)
a Also including terms for maternal age (years), pre-pregnancy BMI (kg/m2), smoking status, gestational age at delivery (weeks), soluble fms-like tirosin-kinasi 1 to placental growth factor ratio, placental weight (g), and placental area (cm2).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Di Martino, D.D.; Avagliano, L.; Ferrazzi, E.; Fusè, F.; Sterpi, V.; Parasiliti, M.; Stampalija, T.; Zullino, S.; Farina, A.; Bulfamante, G.P.; et al. Hypertensive Disorders of Pregnancy and Fetal Growth Restriction: Clinical Characteristics and Placental Lesions and Possible Preventive Nutritional Targets. Nutrients 2022, 14, 3276. https://doi.org/10.3390/nu14163276

AMA Style

Di Martino DD, Avagliano L, Ferrazzi E, Fusè F, Sterpi V, Parasiliti M, Stampalija T, Zullino S, Farina A, Bulfamante GP, et al. Hypertensive Disorders of Pregnancy and Fetal Growth Restriction: Clinical Characteristics and Placental Lesions and Possible Preventive Nutritional Targets. Nutrients. 2022; 14(16):3276. https://doi.org/10.3390/nu14163276

Chicago/Turabian Style

Di Martino, Daniela Denis, Laura Avagliano, Enrico Ferrazzi, Federica Fusè, Vittoria Sterpi, Marco Parasiliti, Tamara Stampalija, Sara Zullino, Antonio Farina, Gaetano Pietro Bulfamante, and et al. 2022. "Hypertensive Disorders of Pregnancy and Fetal Growth Restriction: Clinical Characteristics and Placental Lesions and Possible Preventive Nutritional Targets" Nutrients 14, no. 16: 3276. https://doi.org/10.3390/nu14163276

APA Style

Di Martino, D. D., Avagliano, L., Ferrazzi, E., Fusè, F., Sterpi, V., Parasiliti, M., Stampalija, T., Zullino, S., Farina, A., Bulfamante, G. P., Di Maso, M., & D’Ambrosi, F. (2022). Hypertensive Disorders of Pregnancy and Fetal Growth Restriction: Clinical Characteristics and Placental Lesions and Possible Preventive Nutritional Targets. Nutrients, 14(16), 3276. https://doi.org/10.3390/nu14163276

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop